Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.515, 2006-01, pp. : 15-15
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Standard chemo plus docetaxel does not compromise QOL
Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. :
Access to resources
Recommend
Sorafenib therapy does not compromise the QOL of patients with renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 516, 2006-01 ,pp. :
Exemestane: clinical benefits without QOL compromise
Inpharma, Vol. 1, Iss. 1530, 2006-01 ,pp. :
Exemestane: clinical benefits without QOL compromise
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. :
Valdecoxib does not compromise platelet function
Inpharma, Vol. 1, Iss. 1352, 2002-01 ,pp. :